Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Addi Bioscience Third Quarter 2023 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications, Addi Bioscience. Ms. Graham, please go ahead. Thank you. Good morning and welcome to the Addi Bioscience conference call to provide an operational update and review results for the third quarter 2023. Joining me on the call today, Dr. David Lennon, our president and CEO, Scott Giacobbello, our CFO, and our chief medical officer, Dr. Loretta E. Tree. Today we will provide an overview of operational activity and financial results for the third quarter of 2023 and an update on our Precision 1 trial and clinical development plans going forward. We will open the line for questions at the end of the call following closing comments. A quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors. including those set forth in the risk factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sbc.gov or on our website at www.addibio.com. In ad...